

# Orly Lipsitz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1969505/publications.pdf>

Version: 2024-02-01

37  
papers

4,344  
citations

471509

17  
h-index

330143

37  
g-index

37  
all docs

37  
docs citations

37  
times ranked

5997  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of COVID-19 pandemic on mental health in the general population: A systematic review. <i>Journal of Affective Disorders</i> , 2020, 277, 55-64.	4.1	3,399
2	Government response moderates the mental health impact of COVID-19: A systematic review and meta-analysis of depression outcomes across countries. <i>Journal of Affective Disorders</i> , 2021, 290, 364-377.	4.1	159
3	The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis. <i>Journal of Affective Disorders</i> , 2020, 276, 576-584.	4.1	118
4	The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence. <i>Journal of Affective Disorders</i> , 2020, 274, 903-910.	4.1	70
5	The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis. <i>Journal of Psychiatric Research</i> , 2021, 134, 57-68.	3.1	58
6	The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 120, 78-85.	6.1	48
7	Registered clinical studies investigating psychedelic drugs for psychiatric disorders. <i>Journal of Psychiatric Research</i> , 2021, 139, 71-81.	3.1	47
8	The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. <i>Bipolar Disorders</i> , 2020, 22, 831-840.	1.9	40
9	Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders. <i>CNS Drugs</i> , 2021, 35, 925-934.	5.9	35
10	Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence. <i>Journal of Affective Disorders</i> , 2020, 276, 570-575.	4.1	30
11	The emerging role of psilocybin and MDMA in the treatment of mental illness. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 1263-1273.	2.8	29
12	The Association Between Adverse Childhood Experiences and Inflammation in Patients with Major Depressive Disorder: A Systematic Review. <i>Journal of Affective Disorders</i> , 2020, 272, 1-7.	4.1	28
13	Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review. <i>Journal of Affective Disorders</i> , 2021, 293, 285-294.	4.1	28
14	Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1031-1040.	2.4	25
15	The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic review. <i>Journal of Psychiatric Research</i> , 2021, 137, 232-241.	3.1	25
16	A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions. <i>Journal of Affective Disorders</i> , 2021, 282, 160-164.	4.1	24
17	Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 899-913.	1.2	24
18	Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression. <i>Advances in Therapy</i> , 2021, 38, 2795-2820.	2.9	19

#	ARTICLE	IF	CITATIONS
19	The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE). <i>Psychiatry Research</i> , 2021, 302, 113993.	3.3	16
20	Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 105, 110126.	4.8	12
21	The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence. <i>Journal of Psychopharmacology</i> , 2021, 35, 128-136.	4.0	11
22	Do sleep changes mediate the anti-depressive and anti-suicidal response of intravenous ketamine in treatment-resistant depression?. <i>Journal of Sleep Research</i> , 2022, 31, e13400.	3.2	11
23	Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects. <i>Psychiatry Research</i> , 2021, 306, 114231.	3.3	11
24	The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine. <i>Journal of Affective Disorders</i> , 2021, 294, 592-596.	4.1	10
25	Insulin resistance is associated with deficits in hedonic, self-reported cognitive, and psychosocial functional response to antidepressant treatment in individuals with major depressive disorder. <i>Journal of Affective Disorders</i> , 2021, 282, 448-453.	4.1	9
26	The impact of overweight/obesity on monetary reward processing: A systematic review. <i>Journal of Psychiatric Research</i> , 2021, 137, 456-464.	3.1	9
27	Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation. <i>CNS Spectrums</i> , 2022, 27, 315-321.	1.2	7
28	The influence of prescriber and patient gender on the prescription of benzodiazepines: results from the Florida Medicaid Dataset. <i>CNS Spectrums</i> , 2022, 27, 378-382.	1.2	6
29	Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment. <i>Journal of Affective Disorders</i> , 2021, 288, 210-216.	4.1	6
30	Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?. <i>Journal of Affective Disorders</i> , 2021, 292, 714-719.	4.1	5
31	Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic. <i>Psychiatry Research</i> , 2021, 303, 114086.	3.3	5
32	Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence. <i>CNS Spectrums</i> , 2022, 27, 322-330.	1.2	5
33	Frequency Analysis of Symptomatic Worsening Following Ketamine Infusions For Treatment Resistant Depression in a Real-World Sample: Results From the Canadian Rapid Treatment Centre of Excellence. <i>Psychiatry Research</i> , 2021, 307, 114321.	3.3	5
34	Sex differences in ketamine's therapeutic effects for mood disorders: A systematic review. <i>Psychiatry Research</i> , 2022, 312, 114579.	3.3	5
35	Ketamine monotherapy versus adjunctive ketamine in adults with treatment-resistant depression: Results from the Canadian Rapid Treatment Centre of Excellence. <i>Journal of Psychiatric Research</i> , 2021, 143, 209-214.	3.1	3
36	Effect of body anthropometrics on brain structure of offspring of parents with bipolar disorder. <i>Journal of Psychiatric Research</i> , 2020, 124, 137-142.	3.1	1

#	ARTICLE	IF	CITATIONS
37	Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence. <i>Journal of Psychiatric Research</i> , 2021, 136, 444-451.	3.1	1